Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib Roll-over Study in GIST
NCT01863745Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2013
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in gastrointestinal stromal tumor (GIST), sponsored by Novartis. Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 10.3 years. Started Jun 2013; status: completed.
02
Drugs
nilotinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT01863745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01863745.